The company anouncement on 05/09/2011 regarding Notice of General Meeting to be held on 7 October 2011 states on page 8:
USE OF FUNDS (Re capital raising) approx that;
10% will be used to further the company's Italian and French trial on non-evasive diagnostic test for the detection of breast cancer.
30% toward the identification of any potential new businesses, and the balance
60% for working capital.
They plan to spend 3x more on potential new businesses that further tests re Italian and French trials.
This I believe along with the appointmet of the two new directors (who both have had extensive involvement not in the Medical field but in the Resource Sector), is a strong indication of the future plans of the company.
Nothing else makes sense IMO.
Yes I hold.
FER Price at posting:
1.3¢ Sentiment: LT Buy Disclosure: Held
